Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Public ClinicalTrials.gov record NCT02045797. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
GSK2140944 belongs to a novel structural class of antibiotics - Bacterial Type II Topoisomerase Inhibitors (BTI). This is a Phase II, randomized, two-part, multicenter study designed to select the optimal dose by further characterizing the safety, tolerability and PK of GSK 2140944 and by evaluating efficacy in subjects requiring in-patient medical care to treat their suspected or confirmed Gram-positive acute bacterial skin and skin structure infections (ABSSSI). The selected dose will be used in future studies.
Study identification
- NCT ID
- NCT02045797
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 126 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 24, 2014 (Actual)
- Primary completion
- Jun 29, 2015 (Actual)
- Completion
- Jun 29, 2015 (Actual)
- Last update posted
- Nov 17, 2017
2014 – 2015
United States locations
- U.S. sites
- 30
- U.S. states
- 17
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Phoenix | Arizona | 85021 | — |
| GSK Investigational Site | Anaheim | California | 92804 | — |
| GSK Investigational Site | Chula Vista | California | 91942 | — |
| GSK Investigational Site | La Mesa | California | 91942 | — |
| GSK Investigational Site | Oceanside | California | 92056 | — |
| GSK Investigational Site | Sylmar | California | 91342 | — |
| GSK Investigational Site | Torrance | California | 90502 | — |
| GSK Investigational Site | Miramar | Florida | 33027 | — |
| GSK Investigational Site | West Palm Beach | Florida | 33401 | — |
| GSK Investigational Site | Augusta | Georgia | 30909 | — |
| GSK Investigational Site | Augusta | Georgia | 30912 | — |
| GSK Investigational Site | Council Bluffs | Iowa | 51503 | — |
| GSK Investigational Site | Hazard | Kentucky | 41701 | — |
| GSK Investigational Site | Zachary | Louisiana | 70791 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55422 | — |
| GSK Investigational Site | Carriere | Mississippi | 39426 | — |
| GSK Investigational Site | Jackson | Mississippi | 39216-4505 | — |
| GSK Investigational Site | Butte | Montana | 59701 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68510 | — |
| GSK Investigational Site | Las Vegas | Nevada | 92120 | — |
| GSK Investigational Site | Belleville | New Jersey | 07109 | — |
| GSK Investigational Site | Neptune City | New Jersey | 07753 | — |
| GSK Investigational Site | Albany | New York | 12208 | — |
| GSK Investigational Site | Brooklyn | New York | 11215 | — |
| GSK Investigational Site | Lima | Ohio | 45801 | — |
| GSK Investigational Site | Toledo | Ohio | 43608 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15212 | — |
| GSK Investigational Site | Channelview | Texas | 77530 | — |
| GSK Investigational Site | Houston | Texas | 77024 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02045797, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 17, 2017 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02045797 live on ClinicalTrials.gov.